Emile E. Voest

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 211 publications

Retraction Notice to: Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.

Retraction Notice to: Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.

Journal: Cancer cell
Published: September 05, 2026

Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.

Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.

Journal: bioRxiv : the preprint server for biology
Published: May 25, 2026

Subclonal immune evasion in non-small cell lung cancer.

Subclonal immune evasion in non-small cell lung cancer.

Journal: Cancer cell
Published: May 19, 2026

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.

Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol.

Journal: European journal of cancer (Oxford, England : 1990)
Published: May 07, 2026

Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program.

Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program.

Journal: Cancer discovery
Published: March 13, 2026

Corrigendum to Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.

Corrigendum to Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance.

Journal: The Journal of clinical investigation
Published: March 02, 2026

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

BRAFV600E-mutated central nervous system tumors benefit from treatment with dabrafenib plus trametinib: Results from the Drug Rediscovery Protocol.

Journal: European journal of cancer (Oxford, England : 1990)
Published: February 10, 2026

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

The SHERPA trial: A phase I study combining SHP2 inhibitor RMC-4630 and ERK inhibitor LY3214996 in patients with KRAS-mutant pancreatic, non-small cell lung and colorectal cancer.

Journal: European journal of cancer (Oxford, England : 1990)
Published: November 20, 2025

Prospective evaluation of genomics-guided off-label treatment.

Prospective evaluation of genomics-guided off-label treatment.

Journal: Nature
Published: September 02, 2025

Microbiota-derived metabolites as modulators of cancer immunotherapy response.

Microbiota-derived metabolites as modulators of cancer immunotherapy response.

Journal: Nature communications
Published: August 11, 2025

Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.

Tryptophan degradation by intestinal Bacteroides induces anti-tumor immunity and limits melanoma growth.

Journal: Cell reports. Medicine
Published: June 27, 2025

Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer.

Liver metastases dampen IL18-driven γδ T cell activity and immunotherapy responsiveness in colorectal cancer.

Journal: Cell reports. Medicine
Published: June 18, 2025
Showing 1-12 of 211

Last Updated: 09/26/2026